KALA

KALA BIO, Inc. (KALA) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. KALA BIO, Inc. is a biopharmaceutical company in transition, shifting from its historical focus on biologics (specifically the MSC-S platform and KPI-012) to an "AI platform-as-a-service" model. Following the discontinuation of the KPI-012 clinical trial in September 2025 due to missed endpoints, the company is now focused on monetizing legacy biologics assets and developing the Researgency agentic AI research platform under an exclusive license with Younet. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. The "Short-Term Investments" line item represents a secured promissory note loaned to Minglemint Solutions LLC.

Material Changes vs. Prior Period

• Significant Expense Reduction: Total operating expenses decreased by approximately $18.2 million (84%) compared to the prior year period. This was driven by the cessation of KPI-012 clinical development, resulting in a $12.2 million drop in R&D expenses and a $5.8 million drop in G&A expenses due to workforce reductions.
• Loss on Contingent Consideration: The loss on fair value remeasurement of contingent consideration dropped to $0 from $174,000 in the prior period, reflecting the discontinuation of the underlying clinical program.
• Grant Income Cessation: Grant income from the CIRM Award dropped to $0 from $2.9 million in the prior period, as the associated clinical trial was discontinued.
• Capital Structure Changes:
  • Completed a 1-for-50 reverse stock split on May 8, 2026.
  • Issued and subsequently converted 2,100,000 shares of Series AAA Preferred Stock into common stock in January 2026, raising $4.2 million in gross proceeds.
  • Deployed $7.0 million of cash into a secured loan (Short-term investment) to Minglemint Solutions LLC to optimize yield.

Outlook, Risks, and Management Commentary

• Strategic Pivot: Management is executing a dual-track strategy: (1) monetizing or out-licensing legacy biologics assets (KPI-012, KPI-014) and (2) commercializing the Researgency AI platform. No definitive agreements for asset sales have been reached as of the filing date.
• Liquidity and Going Concern: As of June 30, 2026, cash and cash equivalents were only $229,000. However, management believes liquidity is sufficient for at least 12 months due to the $7.0 million secured note receivable from Minglemint. The company has issued a "Call Notice" demanding repayment of approximately $1.0 million of this note, with repayment expected by late September 2026.
• Operating Budget: The company has adopted a disciplined operating budget of approximately $1.5 million to $3.2 million for the next 12 months, primarily covering legal, audit, compliance, and IP maintenance costs.
• Nasdaq Compliance: The company successfully regained compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) and Minimum Bid Price rules following the reverse stock split.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness related to insufficient personnel following restructuring. Remediation is ongoing.
• Risks: Key risks include the ability to secure additional financing if the Minglemint note is not repaid as expected, the uncertainty of commercializing the AI platform, and the potential inability to monetize legacy biologics assets.

Investor Verification Checklist

• Repayment of Minglemint Note: Verify the receipt of the $1.0 million demanded via Call Notice and the overall collectability of the $7.0 million loan, which is the primary source of near-term liquidity.
• Researgency Platform Progress: Monitor for updates on commercial arrangements or customer deployments for the AI platform, as this is the new core business strategy.
• Asset Monetization: Track any announcements regarding the licensing or sale of the KPI-012/KPI-014 biologics assets.
• Internal Control Remediation: Review future filings for updates on the remediation of the material weakness in internal controls over financial reporting.
• Capital Raises: Watch for utilization of the At-The-Market (ATM) facility or new private placements, given the low cash balance outside of the secured note.